Herceptin "Dear Doctor" Letter To Emphasize Cardiac Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech is reviewing language with FDA to advise of cardiotoxicity risk as it prepares to submit trastuzumab for treatment of adjuvant breast cancer. The firm reports that there have been multiple inquiries to the medical communication group for information on the cardiac monitoring protocol used in the adjuvant trials.